I also had ChatGPT break it down for me!
What Just Happened?
CytoDyn (CYDY) shared new data at ESMO, one of the world’s top cancer conferences.
They treated 28 women with stage 4 triple-negative breast cancer (mTNBC) — the toughest type of breast cancer to treat.
These women had already tried 3-4 other treatments that failed.
Some even had brain tumors (that’s super high-risk).
Basically: they had no options left.
This was “Hail Mary” medicine.
???? What Did They Find?
Survival rates:
Timepoint Leronlimab Results Typical Results (for comparison)
1 year 41% alive ~25% alive
2 years 25% alive <10% alive
3 years 20% alive Nearly 0%
???? Translation:
Most existing drugs barely keep 25% alive for 1 year.
By year 3, almost no one is left.
But with Leronlimab?
20% were still alive after 3 years.
FOUR women are still alive and cancer-free after 3.5 to 4+ years.
That’s huge.
???? Why Is That a Big Deal?
mTNBC is one of the deadliest cancers.
Median survival is usually 6–12 months once it's metastatic.
Cures? Basically unheard of.
This data is real.
Not just a press release.
This is peer-reviewed and presented at ESMO.
That adds serious credibility.
Leronlimab wasn’t expected to cure anyone.
Most thought it might extend life a little.
Instead, some women may have been saved outright.
???? What’s Next?
This was just the abstract — a quick summary.
???? On May 15, CytoDyn will share the full poster presentation.
We’ll probably learn:
How the drug worked (mechanism of action)
Which patients benefited most
Plans for next steps (e.g., new clinical trials, FDA talks, partnerships)
???? Where Does This Go Now?
Right now, Wall Street hasn’t reacted.
No big headlines. No media frenzy.
But:
This is the strongest data CytoDyn has ever put out.
It’s the moment believers have waited years for.
If the market catches on?
This could move from “penny stock” to biotech comeback story.
???? The Bottom Line?
Leronlimab just posted historic survival results in a cancer where long-term survival is almost impossible.
4 women may now be completely cancer-free.
The data is peer-reviewed and public.
The world hasn’t caught on yet.
If this holds up with more data?
???? It could change lives — and the entire cancer treatment landscape.
What Just Happened?
CytoDyn (CYDY) shared new data at ESMO, one of the world’s top cancer conferences.
They treated 28 women with stage 4 triple-negative breast cancer (mTNBC) — the toughest type of breast cancer to treat.
These women had already tried 3-4 other treatments that failed.
Some even had brain tumors (that’s super high-risk).
Basically: they had no options left.
This was “Hail Mary” medicine.
???? What Did They Find?
Survival rates:
Timepoint Leronlimab Results Typical Results (for comparison)
1 year 41% alive ~25% alive
2 years 25% alive <10% alive
3 years 20% alive Nearly 0%
???? Translation:
Most existing drugs barely keep 25% alive for 1 year.
By year 3, almost no one is left.
But with Leronlimab?
20% were still alive after 3 years.
FOUR women are still alive and cancer-free after 3.5 to 4+ years.
That’s huge.
???? Why Is That a Big Deal?
mTNBC is one of the deadliest cancers.
Median survival is usually 6–12 months once it's metastatic.
Cures? Basically unheard of.
This data is real.
Not just a press release.
This is peer-reviewed and presented at ESMO.
That adds serious credibility.
Leronlimab wasn’t expected to cure anyone.
Most thought it might extend life a little.
Instead, some women may have been saved outright.
???? What’s Next?
This was just the abstract — a quick summary.
???? On May 15, CytoDyn will share the full poster presentation.
We’ll probably learn:
How the drug worked (mechanism of action)
Which patients benefited most
Plans for next steps (e.g., new clinical trials, FDA talks, partnerships)
???? Where Does This Go Now?
Right now, Wall Street hasn’t reacted.
No big headlines. No media frenzy.
But:
This is the strongest data CytoDyn has ever put out.
It’s the moment believers have waited years for.
If the market catches on?
This could move from “penny stock” to biotech comeback story.
???? The Bottom Line?
Leronlimab just posted historic survival results in a cancer where long-term survival is almost impossible.
4 women may now be completely cancer-free.
The data is peer-reviewed and public.
The world hasn’t caught on yet.
If this holds up with more data?
???? It could change lives — and the entire cancer treatment landscape.
4
